Mycophenolatedosage

mycophenolate mofetil 250 MG Oral Capsule

Dosage and administration

ADULTS DOSAGE Kidne y Transplant 1 g twice daily orally Heart Transplant 1.5 g twice daily orally L i ve r Transplant 1.5 g twice daily orally PEDIATRICS Kidne y Transplant 600 mg/m 2 orally twice daily, up to maximum of 2 g daily Heart Transplant 600 mg/m 2 orally twice daily (starting dose) up to a maximum of 900 mg/m 2 twice daily (3 g) Liver Transplant 600 mg/m 2 orally twice daily (starting dose) up to a maximum of 900 mg/m 2 twice daily (3 g)

Mycophenolate mofetil Intravenous is an alternative when patients cannot tolerate oral medication. Administer within 24 hours following transplantation, until patients can tolerate oral medication, up to 14 days.

Reduce or interrupt dosing in the event of neutropenia.

See full prescribing information (FPI) for: adjustments for renal impairment and neutropenia.

2.1 Important

Administration Instructions Mycophenolate mofetil should not be used without the supervision of a physician with experience in immunosuppressive therapy. Mycophenolate Mofetil Capsules Mycophenolate mofetil capsules should not be used interchangeably with mycophenolic acid delayed-release tablets without supervision of a physician with experience in immunosuppressive therapy because the rates of absorption following the administration of mycophenolate mofetil capsule and mycophenolic acid delayed-release tablets are not equivalent. Mycophenolate mofetil capsules should not be opened or crushed. Patients should avoid inhalation or contact of the skin or mucous membranes with the powder contained in Mycophenolate mofetil capsules. If such contact occurs, they must wash the area of contact thoroughly with soap and water. In case of ocular contact, rinse eyes with plain water. The initial oral dose of mycophenolate mofetil capsules should be given as soon as possible following kidney, heart or liver transplant. It is recommended that mycophenolate mofetil capsules be administered on an empty stomach. In stable transplant patients, however, mycophenolate mofetil capsules may be administered with food if necessary. Patients should be instructed to take a missed dose as soon as they remember, except if it is closer than 2 hours to the next scheduled dose; in this case, they should continue to take mycophenolate mofetil capsules at the usual times.

2.2 Dosage Recommendations for

Kidney Transplant Patients Adults The recommended dosage for adult kidney transplant patients is 1 g orally, twice daily (total daily dose of 2 g). Pediatrics (3 months and older) Pediatric dosing is based on body surface area (BSA). Pediatric patients with BSA ≥ 1.25 m 2 may be dosed with capsules as follows: Table 1 Pediatric Kidney Transplant: Dosage Using Capsules B od y Surface Area Dosage 1.25 m 2 to <1.5 m 2 Mycophenolate mofetil capsule 750 mg twice daily (1.5 g total daily dose) ≥ 1.5 m 2 Mycophenolate mofetil capsules 1 g twice daily (2 g total daily dose)

2.3 Dosage Recommendations for

Heart Transplant Patients Adults The recommended dosage of mycophenolate mofetil capsules for adult heart transplant patients is 1.5 g orally administered twice daily (total daily dose of 3 g). Pediatrics (3 months and older) Pediatric patients with BSA ≥1.25 m 2 may be started on therapy with capsules as follows: Table 2 Pediatric Heart Transplant: Pediatric Starting Dosage Using Capsules B od y Surface Area Starting Dosage * 1.25 m 2 to <1.5 m 2 Mycophenolate mofetil capsule 750 mg twice daily (1.5 g total daily dose) ≥ 1.5 m 2 Mycophenolate mofetil capsules 1 g twice daily (2 g total daily dose) *Maximum maintenance dose: 3 g total daily.

2.4 Dosage Recommendations for

Liver Transplant Patients Adults The recommended dosage of mycophenolate mofetil capsules for adult liver transplant patients is 1.5 g administered orally twice daily (total daily dose of 3 g). Pediatrics (3 months and older) Pediatric patients with BSA ≥1.25 m 2 may be started on therapy with capsules as follows: Table 3 Pediatric Liver Transplant: Pediatric Starting Dosage Using Capsules B od y Surface Area Starting Dosage * 1.25 m 2 to <1.5 m 2 Mycophenolate mofetil capsule 750 mg twice daily (1.5 g total daily dose) ≥ 1.5 m 2 Mycophenolate mofetil capsules 1 g twice daily (2 g total daily dose) *Maximum maintenance dose: 3 g total daily.

2.5 Dosage Modifications:

Patients with Renal Impairment, Neutropenia Renal Impairment No dosage modifications are needed in kidney transplant patients with delayed graft function postoperatively. In kidney transplant patients with severe chronic impairment of the graft (GFR <25 mL/min/1.73 m 2 ), do not administer doses of mycophenolate mofetil capsules greater than 1 g twice a day. These patients should be carefully monitored. Neutropenia If neutropenia develops (ANC <1.3 x 10 3 /µL), dosing with mycophenolate mofetil capsules should be interrupted or reduced, appropriate diagnostic tests performed, and the patient managed appropriately.

Text above is quoted in full from the FDA-approved drug label published by openFDA, effective August 2, 2025. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.

This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.

See what it costs — price without insurance